Page 14 - Research Models News Today

Community Capital Management LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 7.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,000 shares of the medical research company’s stock after buying an additional […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,700,000 shares, a growth of 10.4% from the August 31st total of 1,540,000 shares. Based on an average daily volume of 480,300 shares, the […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price target cut by TD Cowen from $212.00 to $209.00 in a report released on Monday, Benzinga reports. They currently have a market perform rating on the medical research company’s stock. CRL has been the topic of a number of other reports. Robert W. Baird […]

Signature Estate & Investment Advisors LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 7.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,596 shares of the medical research company’s stock after purchasing an additional 819 […]

Signature Estate & Investment Advisors LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 7.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 11,596 shares of the medical research company’s stock after purchasing an additional 819 shares during the period. Signature Estate & Investment Advisors LLC’s holdings […]

Norris Perne & French LLP MI grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 102,813 shares of the medical research company’s stock after buying an additional 1,267 shares during the quarter. Charles River Laboratories International […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective trimmed by Robert W. Baird from $267.00 to $256.00 in a report issued on Friday, MarketBeat.com reports. The firm currently has an outperform rating on the medical research company’s stock. Several other equities research analysts have also weighed in on the company. Bank […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective reduced by Bank of America from $245.00 to $230.00 in a report issued on Friday morning, FlyOnTheWall reports. Other equities research analysts have also recently issued research reports about the company. TD Cowen initiated coverage on Charles River Laboratories International in a research […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its target price reduced by Wells Fargo & Company from $280.00 to $275.00 in a research report released on Friday morning, Marketbeat Ratings reports. They currently have an overweight rating on the medical research company’s stock. A number of other equities research analysts have also recently […]

Charles River Laboratories International (NYSE:CRL – Free Report) had its price objective reduced by Guggenheim from $255.00 to $225.00 in a research note published on Friday morning, MarketBeat reports. They currently have a buy rating on the medical research company’s stock. A number of other equities research analysts have also recently weighed in on CRL. […]